Nuage Therapeutics SL

Based in Spain, Nuage Therapeutics SL specializes in drug discovery that targets intrinsically disordered proteins (IDPs), aiming to innovate therapies for aggressive cancers and other complex diseases. Founded in 2021 in Barcelona, Spain, Nuage Therapeutics SL focuses on drug discovery targeting IDPs. The company has successfully completed 2 deals, with its most recent funding round, a Seed round of EUR 12. 000 mn, occurring on June 20, 2023.

Investors included Asabys Partners, Bstartup Banco Sabadell, Center for Technological & Industrial Development, and Sofinnova Partners. The company is led by CEO Judit Folgueira, alongside co-founders Denes Hnisz, Mateusz Biesaga, and Xavier Salvatella. Nuage Therapeutics focuses on pioneering drug discovery targeting intrinsically disordered proteins (IDPs), which represent a significant portion of the human proteome. The company’s primary offerings revolve around innovative therapies aimed at treating aggressive cancers, particularly those associated with oncogenic transcription factors that defy traditional drug development techniques.

By utilizing the unique properties of IDPs to form transient self-assembled higher-order structures, Nuage aims to unlock new therapeutic avenues for oncology. Beyond cancer, the technology is also applicable in other therapeutic areas, such as neurodegenerative diseases and autoimmune disorders. Geographically, Nuage is positioning its products for markets such as North America and Europe, where there is a robust demand for advanced cancer therapies. The revenue model for Nuage Therapeutics is structured around collaborations and partnerships with pharmaceutical companies and research institutions, providing them with access to their innovative drug development platform.

This model enables clients to engage in co-development agreements, allowing for shared investment in the research and commercialization of new therapies. Revenue is generated through milestone payments linked to the advancement of drug candidates, as well as potential royalties from successful product launches. The company’s flagship offerings are tied to breakthrough therapies derived from their unique approach to targeting disordered proteins, with pricing structures reflective of the high-value nature of their solutions. Overall, the financial framework supports long-term relationships within the biopharmaceutical industry, focusing on delivering transformative health solutions.

In June 2023, Nuage Therapeutics raised EUR 12. 000 mn in Seed funding, co-led by returning investor Asabys Partners and new investor Sofinnova Partners, alongside contributions from Bstartup Banco Sabadell and the Center for Technological & Industrial Development. The company plans to utilize this funding to advance its drug discovery platform. Future growth initiatives include the design and launch of new products within the oncology space, with anticipated expansions targeting North America and Europe by the end of 2024.